National Resilience’s subsidiary Resilience Government Services has received around $17.5m in funding for expanding critical medicine components manufacturing.
Resilience received the funding from the US Department of Health and Human Services’ Administration for Strategic Preparedness and Response’s Center for Industrial Base Management and Supply Chain.
Go deeper with GlobalData
This funding will be used for domestic pharmaceutical manufacturing expansion, enhancing the production of essential medicine components. It will help secure the supply chain for key starting materials and active pharmaceutical ingredients (APIs).
The financial injection is part of a collaboration with the public-private partnership, Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), focused on strengthening the domestic biomanufacturing sector for medical countermeasures.
Resilience has joined forces with Aralez Bio, a biotech company specialising in advanced amino acids production, to utilise biocatalysis technology.
Under the agreement, Resilience will employ its certified good manufacturing process (cGMP) facilities, analytical development, and regulatory expertise to reinforce the pharmaceutical supply chain.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataResilience CEO Rahul Singhvi said: “Securing this manufacturing programme for Resilience is a good step forward for the US pharmaceutical manufacturing industry to ensure a more resilient and responsive supply chain.
“With the support from both public and private sectors, we are positioned to enhance and expand domestic production of key starting materials and active pharmaceutical ingredients that often fall into short supply.”
This initiative is crucial for ensuring the continuous availability of life-saving medications that are currently in short supply.
It aligns with the BioMaP-Consortium’s goal to bridge the gaps in pharmaceutical manufacturing via public-private partnerships.
The funding will facilitate cGMP manufacturing with Aralez Bio’s advanced technology, aiming to streamline API production processes in the US and meet the Food and Drug Administration’s requirements for Resilience to become an approved domestic supplier of APIs.
Aralez Bio CEO Tina Boville said: “Aralez Bio’s proprietary enzyme platform is at the forefront of amino acid chemistry. When combined with Resilience’s groundbreaking approach to revolutionising pharmaceutical manufacturing, this collaboration is strengthening the security of our supply chains.”
In March 2023, National Resilience secured a $410m long-term loan financing deal to establish an end-to-end biomanufacturing capacity.
